-
Mashup Score: 3Selinexor Combined With Ruxolitinib Shows Promising Results in Patients With MF and Poor Ruxolitinib | Blood Cancers Today - 1 day(s) ago
Combined with the exporter-1 inhibitor, selinexor, ruxolitinib reduces spleen volume and reduces symptoms for participants with MF who did not respond well to JAK inhibitors.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2Promising Tolerability and Symptom Reduction Using PXS-5505 in Myelofibrosis | Blood Cancers Today - 2 day(s) ago
Combining ruxolitinib with the first-in-class pan-lysyl oxidase inhibitor PXS-5505 improved symptoms over time for participants with myelofibrosis, phase 1/2a research shows.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Combining ruxolitinib with the first-in-class pan-lysyl oxidase inhibitor PXS-5505 improved symptoms over time for patients with #myelofibrosis, according to a study presented at #ASH24. 📰 Read more: https://t.co/kaKqGsHnXh https://t.co/pkADgzidPe
-
-
Mashup Score: 5HOPE-PMF Trial Set to Investigate Interferon-Based Therapy for Early and Low-Risk PMF | Blood Cancers Today - 11 day(s) ago
The soon-opening phase 3 HOPE-PMF trial will investigate the efficacy of interferon-based therapy, ropeginterferon alfa-2b (ropeg), for early and lower-risk primary myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
The phase III HOPE-PMF trial will investigate the efficacy of interferon-based therapy, ropeginterferon alfa-2b, for early and lower-risk primary #myelofibrosis. @GhaithAbuZeinah, of @WeillCornell, presented the study's design at #ASH24. 📚 Read more: https://t.co/bN1rdWZObf https://t.co/P1TZI46C0g
-
-
Mashup Score: 0Bomedemstat Plus Ruxolitinib Promissing for First- and Second-Line MDS | Blood Cancers Today - 20 day(s) ago
The combination of bomedemstat and ruxolitinib showed promising tolerability in first- and second-line MF treatment, with reductions in symptoms and spleen size.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
☑️ Bomedemstat and ruxolitinib showed promising tolerability in first- and second-line #myelofibrosis treatment, with reductions in symptoms and spleen size, according to a study presented at #ASH24. 📚 Read more: https://t.co/tYh1AcLYBl https://t.co/tV44YKjElB
-
-
Mashup Score: 1BET Inhibitor Shows Encouraging Safety and Tolerability in Myelofibrosis | Blood Cancers Today - 21 day(s) ago
The phase 1 study found that INCB057643, as monotherapy or in combination with ruxolitinib, was generally well tolerated in patients with relapsed or refractory MF.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
INCB057643, as monotherapy or in combination with ruxolitinib, was generally well tolerated in patients with relapsed or refractory #myelofibrosis. Read more from the study presented at #ASH24 by @JustinWattsMD of @SylvesterCancer @UMiamiHealth. ➡️ https://t.co/ugV3UGPEDE https://t.co/Tq8r7tK0Db
-
☑️ Selinexor plus ruxolitinib shows promising results in patients with #myelofibrosis and poor ruxolitinib response, according to a study presented at #ASH24. 📚 Read here: https://t.co/V7M6Opd5c9 https://t.co/kwq9yKtqf3